Similarly, prospective clinical trials also confirmed that the CDK4/6 inhibitor, palbociclib, the mTOR inhibitor, everolimus, and the PI3K inhibitor, buparlisib may improve progression-free survival (PFS) in patients with advanced breast cancer [39–42]. Here, CDK4 is linked to breast cancer.